| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Evidence-Based Medicine | 39 | 2021 | 3228 | 4.50 | Why? |
| Practice Guidelines as Topic | 37 | 2021 | 15421 | 2.37 | Why? |
| Network Meta-Analysis | 7 | 2019 | 426 | 1.92 | Why? |
| Decision Making | 19 | 2021 | 3132 | 1.91 | Why? |
| Bias | 9 | 2018 | 1109 | 1.77 | Why? |
| Health Services | 4 | 2017 | 765 | 1.41 | Why? |
| Research Report | 4 | 2019 | 376 | 1.33 | Why? |
| Comprehension | 2 | 2018 | 259 | 1.12 | Why? |
| Diagnostic Tests, Routine | 5 | 2017 | 2643 | 1.05 | Why? |
| Evidence-Based Practice | 7 | 2018 | 693 | 1.04 | Why? |
| Review Literature as Topic | 6 | 2018 | 387 | 1.02 | Why? |
| Information Dissemination | 4 | 2019 | 2986 | 0.95 | Why? |
| Venous Thromboembolism | 7 | 2021 | 4273 | 0.88 | Why? |
| Randomized Controlled Trials as Topic | 14 | 2020 | 10649 | 0.87 | Why? |
| Dentin Sensitivity | 1 | 2018 | 2 | 0.79 | Why? |
| Toothpastes | 1 | 2018 | 24 | 0.78 | Why? |
| Deja Vu | 1 | 2018 | 2 | 0.77 | Why? |
| Clinical Decision-Making | 7 | 2019 | 3755 | 0.76 | Why? |
| Research Design | 10 | 2018 | 5830 | 0.75 | Why? |
| Policy Making | 5 | 2018 | 829 | 0.75 | Why? |
| Patient Outcome Assessment | 3 | 2018 | 707 | 0.75 | Why? |
| Checklist | 3 | 2018 | 714 | 0.70 | Why? |
| Anticoagulants | 10 | 2021 | 9563 | 0.69 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 220 | 0.67 | Why? |
| Histamine H1 Antagonists | 1 | 2017 | 79 | 0.66 | Why? |
| Emergencies | 4 | 2021 | 4095 | 0.65 | Why? |
| Decision Making, Organizational | 1 | 2017 | 104 | 0.64 | Why? |
| Conflict of Interest | 1 | 2018 | 175 | 0.62 | Why? |
| Patient Preference | 3 | 2018 | 750 | 0.61 | Why? |
| Administrative Personnel | 2 | 2018 | 326 | 0.60 | Why? |
| Free Radical Scavengers | 1 | 2016 | 82 | 0.60 | Why? |
| Hematology | 2 | 2021 | 649 | 0.59 | Why? |
| Expert Testimony | 1 | 2019 | 658 | 0.58 | Why? |
| Delivery of Health Care | 11 | 2018 | 15909 | 0.58 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2017 | 265 | 0.58 | Why? |
| Anti-Allergic Agents | 1 | 2017 | 167 | 0.58 | Why? |
| Medical Tourism | 1 | 2015 | 53 | 0.57 | Why? |
| Public Health | 8 | 2018 | 16359 | 0.56 | Why? |
| Acetylcysteine | 1 | 2016 | 255 | 0.50 | Why? |
| Insurance Coverage | 1 | 2017 | 348 | 0.49 | Why? |
| Idiopathic Pulmonary Fibrosis | 2 | 2016 | 595 | 0.46 | Why? |
| Quality of Health Care | 3 | 2017 | 1948 | 0.44 | Why? |
| Environmental Exposure | 2 | 2018 | 1558 | 0.43 | Why? |
| Pyridones | 1 | 2016 | 738 | 0.40 | Why? |
| Rhinitis, Allergic | 1 | 2017 | 704 | 0.40 | Why? |
| Anti-Infective Agents | 1 | 2021 | 1766 | 0.38 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.36 | Why? |
| Educational Technology | 1 | 2008 | 101 | 0.35 | Why? |
| Refugees | 1 | 2017 | 809 | 0.34 | Why? |
| Humans | 100 | 2021 | 930598 | 0.34 | Why? |
| Indoles | 1 | 2016 | 1243 | 0.33 | Why? |
| Patient Dropouts | 2 | 2017 | 96 | 0.33 | Why? |
| Breast Neoplasms | 3 | 2019 | 3633 | 0.32 | Why? |
| Clinical Competence | 2 | 2019 | 3263 | 0.31 | Why? |
| Quality Assurance, Health Care | 2 | 2011 | 596 | 0.31 | Why? |
| Quality of Life | 7 | 2018 | 9820 | 0.31 | Why? |
| Health Policy | 5 | 2021 | 6242 | 0.31 | Why? |
| Publication Bias | 3 | 2018 | 241 | 0.30 | Why? |
| Communicable Diseases | 2 | 2017 | 2148 | 0.30 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.29 | Why? |
| Heparin, Low-Molecular-Weight | 5 | 2018 | 1731 | 0.28 | Why? |
| Video Games | 1 | 2008 | 270 | 0.28 | Why? |
| Attitude of Health Personnel | 3 | 2018 | 4741 | 0.27 | Why? |
| European Union | 3 | 2017 | 565 | 0.27 | Why? |
| Choice Behavior | 2 | 2018 | 319 | 0.27 | Why? |
| Data Accuracy | 3 | 2018 | 715 | 0.27 | Why? |
| Guidelines as Topic | 5 | 2021 | 2844 | 0.26 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.26 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 3832 | 0.24 | Why? |
| Vulnerable Populations | 4 | 2017 | 3099 | 0.24 | Why? |
| World Health Organization | 4 | 2020 | 4213 | 0.24 | Why? |
| Internal Medicine | 1 | 2008 | 557 | 0.24 | Why? |
| User-Computer Interface | 1 | 2008 | 1068 | 0.23 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.22 | Why? |
| Heparin | 5 | 2018 | 2600 | 0.22 | Why? |
| Health Equity | 3 | 2017 | 1223 | 0.22 | Why? |
| Lost to Follow-Up | 2 | 2017 | 79 | 0.21 | Why? |
| Masks | 2 | 2020 | 8528 | 0.21 | Why? |
| Rheumatology | 3 | 2021 | 1213 | 0.21 | Why? |
| Meta-Analysis as Topic | 3 | 2018 | 1289 | 0.21 | Why? |
| Qualitative Research | 4 | 2018 | 4337 | 0.21 | Why? |
| Uncertainty | 4 | 2019 | 1888 | 0.20 | Why? |
| Disease Outbreaks | 2 | 2018 | 27595 | 0.20 | Why? |
| Teaching | 1 | 2008 | 1208 | 0.19 | Why? |
| Conjunctivitis, Bacterial | 1 | 2018 | 6 | 0.19 | Why? |
| Cost-Benefit Analysis | 3 | 2018 | 2259 | 0.19 | Why? |
| Decision Support Techniques | 3 | 2020 | 903 | 0.18 | Why? |
| Attitude | 2 | 2018 | 1481 | 0.18 | Why? |
| Random Allocation | 2 | 2018 | 773 | 0.18 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.18 | Why? |
| Eye Protective Devices | 1 | 2020 | 245 | 0.17 | Why? |
| Diagnosis | 1 | 2017 | 71 | 0.17 | Why? |
| Drug Administration Schedule | 3 | 2018 | 2324 | 0.17 | Why? |
| Health Planning Guidelines | 1 | 2017 | 133 | 0.16 | Why? |
| Technology Assessment, Biomedical | 1 | 2018 | 106 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Coronavirus | 3 | 2020 | 18339 | 0.16 | Why? |
| Precancerous Conditions | 1 | 2017 | 108 | 0.16 | Why? |
| Social Values | 1 | 2017 | 109 | 0.16 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2017 | 114 | 0.16 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.16 | Why? |
| Internationality | 2 | 2021 | 3297 | 0.16 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.15 | Why? |
| Societies, Medical | 4 | 2021 | 6907 | 0.15 | Why? |
| Cadaver | 1 | 2020 | 626 | 0.15 | Why? |
| Nutrition Policy | 1 | 2017 | 132 | 0.15 | Why? |
| Chlamydia Infections | 1 | 2018 | 248 | 0.15 | Why? |
| Industry | 1 | 2018 | 347 | 0.15 | Why? |
| Epidemiologic Research Design | 1 | 2017 | 166 | 0.14 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.14 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.14 | Why? |
| Health Resources | 2 | 2018 | 2592 | 0.14 | Why? |
| Models, Animal | 1 | 2018 | 788 | 0.14 | Why? |
| Oxidative Stress | 1 | 2005 | 2050 | 0.14 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.14 | Why? |
| Arthritis, Rheumatoid | 2 | 2018 | 2043 | 0.14 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.13 | Why? |
| Post-Exposure Prophylaxis | 1 | 2018 | 472 | 0.13 | Why? |
| Communicable Disease Control | 3 | 2020 | 29620 | 0.13 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.13 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.13 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.13 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.13 | Why? |
| Catheterization, Central Venous | 1 | 2018 | 458 | 0.13 | Why? |
| Information Storage and Retrieval | 1 | 2018 | 644 | 0.12 | Why? |
| Antidepressive Agents | 1 | 2018 | 509 | 0.12 | Why? |
| Risk Assessment | 7 | 2018 | 25439 | 0.12 | Why? |
| Neoplasms | 4 | 2018 | 17251 | 0.12 | Why? |
| Health Plan Implementation | 1 | 2017 | 571 | 0.12 | Why? |
| Dentistry | 1 | 2018 | 621 | 0.12 | Why? |
| Thrombosis | 2 | 2018 | 7504 | 0.11 | Why? |
| Hemorrhage | 3 | 2018 | 3013 | 0.11 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.11 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.11 | Why? |
| Troponin T | 1 | 2017 | 771 | 0.11 | Why? |
| Europe | 2 | 2019 | 12702 | 0.11 | Why? |
| Consumer Behavior | 1 | 2018 | 544 | 0.11 | Why? |
| Drug Resistance, Bacterial | 1 | 2021 | 1414 | 0.11 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.11 | Why? |
| Rare Diseases | 1 | 2015 | 373 | 0.11 | Why? |
| Reference Standards | 1 | 2015 | 1163 | 0.11 | Why? |
| Ontario | 1 | 2018 | 1966 | 0.11 | Why? |
| Metformin | 1 | 2018 | 640 | 0.11 | Why? |
| New York | 3 | 2008 | 2488 | 0.10 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.10 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.10 | Why? |
| Early Detection of Cancer | 2 | 2019 | 1956 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Bayes Theorem | 2 | 2018 | 3237 | 0.10 | Why? |
| Female | 18 | 2019 | 380317 | 0.10 | Why? |
| Treatment Outcome | 6 | 2018 | 51732 | 0.10 | Why? |
| Urologic Surgical Procedures | 1 | 2018 | 996 | 0.10 | Why? |
| Advisory Committees | 1 | 2017 | 1418 | 0.10 | Why? |
| Feedback, Psychological | 1 | 2008 | 21 | 0.10 | Why? |
| Saudi Arabia | 2 | 2017 | 4423 | 0.10 | Why? |
| Fibrinolytic Agents | 2 | 2018 | 1702 | 0.10 | Why? |
| Uterine Cervical Neoplasms | 1 | 2017 | 842 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Venous Thrombosis | 3 | 2018 | 2739 | 0.09 | Why? |
| Mass Screening | 2 | 2019 | 8005 | 0.09 | Why? |
| Anti-Bacterial Agents | 2 | 2021 | 10083 | 0.09 | Why? |
| Male | 15 | 2019 | 367725 | 0.09 | Why? |
| Internship and Residency | 1 | 2008 | 4987 | 0.08 | Why? |
| Depressive Disorder | 1 | 2018 | 1236 | 0.08 | Why? |
| Mediterranean Region | 2 | 2018 | 276 | 0.08 | Why? |
| Forced Expiratory Volume | 2 | 2011 | 632 | 0.08 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.08 | Why? |
| Television | 1 | 2008 | 224 | 0.08 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.08 | Why? |
| Thiobarbituric Acid Reactive Substances | 1 | 2005 | 20 | 0.08 | Why? |
| Chromans | 1 | 2005 | 8 | 0.08 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 2 | 2018 | 3629 | 0.08 | Why? |
| Software | 1 | 2018 | 2501 | 0.08 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.08 | Why? |
| Glutathione Peroxidase | 1 | 2005 | 83 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.08 | Why? |
| Germany | 2 | 2018 | 9196 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Aldehyde Oxidoreductases | 1 | 2003 | 4 | 0.07 | Why? |
| Feasibility Studies | 2 | 2017 | 3467 | 0.07 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.07 | Why? |
| Pulmonary Embolism | 3 | 2018 | 4775 | 0.07 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Vital Capacity | 1 | 2005 | 399 | 0.07 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.06 | Why? |
| Glutathione | 1 | 2005 | 280 | 0.06 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.06 | Why? |
| Risk Factors | 5 | 2018 | 71621 | 0.06 | Why? |
| Secondary Prevention | 2 | 2018 | 762 | 0.06 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.06 | Why? |
| Biomarkers | 1 | 2005 | 23361 | 0.06 | Why? |
| International Cooperation | 1 | 2015 | 3436 | 0.06 | Why? |
| Multivariate Analysis | 2 | 2019 | 5440 | 0.06 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Confidence Intervals | 1 | 2003 | 744 | 0.05 | Why? |
| Animals | 3 | 2020 | 78931 | 0.05 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.05 | Why? |
| Child | 3 | 2018 | 70012 | 0.05 | Why? |
| Upper Extremity Deep Vein Thrombosis | 1 | 2018 | 8 | 0.05 | Why? |
| Pyloric Stenosis | 1 | 2018 | 1 | 0.05 | Why? |
| Erythromycin | 1 | 2018 | 17 | 0.05 | Why? |
| Adult | 7 | 2019 | 244371 | 0.05 | Why? |
| Trimethoprim | 1 | 2018 | 22 | 0.05 | Why? |
| Mortuary Practice | 1 | 2020 | 110 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Communication | 1 | 2017 | 5206 | 0.05 | Why? |
| Personal Satisfaction | 1 | 2008 | 1243 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.04 | Why? |
| Dalteparin | 1 | 2018 | 57 | 0.04 | Why? |
| Planning Techniques | 1 | 2017 | 97 | 0.04 | Why? |
| Travel | 1 | 2017 | 7220 | 0.04 | Why? |
| Perioperative Care | 1 | 2008 | 1329 | 0.04 | Why? |
| Odds Ratio | 2 | 2013 | 5861 | 0.04 | Why? |
| Vaginal Smears | 1 | 2017 | 89 | 0.04 | Why? |
| Immunosuppressive Agents | 1 | 2016 | 6331 | 0.04 | Why? |
| Chlamydia trachomatis | 1 | 2018 | 172 | 0.04 | Why? |
| MEDLINE | 1 | 2017 | 76 | 0.04 | Why? |
| Evaluation Studies as Topic | 1 | 2018 | 391 | 0.04 | Why? |
| Middle Aged | 8 | 2019 | 270681 | 0.04 | Why? |
| United States | 2 | 2021 | 46150 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Blood Loss, Surgical | 1 | 2018 | 211 | 0.04 | Why? |
| Group Processes | 1 | 2018 | 210 | 0.04 | Why? |
| Lung | 1 | 2005 | 31049 | 0.04 | Why? |
| Judgment | 1 | 2017 | 98 | 0.04 | Why? |
| Organizational Case Studies | 1 | 2017 | 293 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2019 | 606 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Vitamin K | 1 | 2018 | 263 | 0.04 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Iatrogenic Disease | 1 | 2018 | 304 | 0.04 | Why? |
| Conservative Treatment | 1 | 2018 | 349 | 0.04 | Why? |
| Thrombocytopenia | 2 | 2018 | 2093 | 0.03 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.03 | Why? |
| Catheter-Related Infections | 1 | 2018 | 381 | 0.03 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.03 | Why? |
| Government Programs | 1 | 2017 | 512 | 0.03 | Why? |
| Colombia | 1 | 2017 | 1241 | 0.03 | Why? |
| Walking | 1 | 2017 | 442 | 0.03 | Why? |
| Endpoint Determination | 1 | 2013 | 344 | 0.03 | Why? |
| Alcohol Drinking | 1 | 2003 | 1663 | 0.03 | Why? |
| Orthopedics | 1 | 2003 | 1279 | 0.03 | Why? |
| Adrenergic beta-Agonists | 1 | 2011 | 93 | 0.03 | Why? |
| Cholinergic Antagonists | 1 | 2011 | 56 | 0.03 | Why? |
| Aged | 5 | 2019 | 215776 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Internet | 1 | 2008 | 6204 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.03 | Why? |
| Polysaccharides | 1 | 2018 | 854 | 0.03 | Why? |
| Patient-Centered Care | 1 | 2018 | 860 | 0.02 | Why? |
| Genetic Variation | 1 | 2003 | 3919 | 0.02 | Why? |
| Medical History Taking | 1 | 2011 | 350 | 0.02 | Why? |
| Blood Transfusion | 1 | 2018 | 1399 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.02 | Why? |
| Spirometry | 1 | 2011 | 524 | 0.02 | Why? |
| Canada | 1 | 2021 | 6018 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.02 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.02 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.02 | Why? |
| Lung Neoplasms | 1 | 2003 | 3228 | 0.02 | Why? |
| Bronchodilator Agents | 1 | 2011 | 444 | 0.02 | Why? |
| Thrombolytic Therapy | 1 | 2017 | 2218 | 0.02 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.02 | Why? |
| Physical Examination | 1 | 2011 | 755 | 0.02 | Why? |
| Young Adult | 1 | 2016 | 93724 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.02 | Why? |
| Azithromycin | 1 | 2018 | 3943 | 0.02 | Why? |
| Psychometrics | 1 | 2010 | 1269 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2018 | 5993 | 0.01 | Why? |
| Exercise Therapy | 1 | 2011 | 976 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Patient Education as Topic | 1 | 2011 | 1476 | 0.01 | Why? |
| Energy Intake | 1 | 2003 | 323 | 0.01 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.01 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2011 | 7268 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2011 | 6537 | 0.01 | Why? |
| Hospital Mortality | 1 | 2018 | 22087 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Genotype | 1 | 2003 | 4697 | 0.01 | Why? |
| Diet | 1 | 2003 | 2052 | 0.01 | Why? |
| Depression | 1 | 2013 | 14116 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |